Tarsus Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $48,118 | $40,813 | $27,614 | $13,076 |
Gross Profit | 44,876 | 37,809 | 25,960 | 11,860 |
EBITDA | -20,675 | -30,942 | -34,478 | -40,566 |
EBIT | -20,959 | -31,181 | -34,748 | -40,913 |
Net Income | -23,420 | -33,290 | -35,731 | -41,902 |
Net Change In Cash | 48,118 | 40,813 | 27,614 | 13,076 |
Free Cash Flow | -8,934 | -15,443 | -37,963 | -35,335 |
Cash | 176,210 | 181,095 | 193,705 | 224,947 |
Basic Shares | 38,381 | 37,823 | 35,300 | 31,944 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $17,447 | $25,816 | $57,027 | $33,432 |
Gross Profit | 15,854 | 24,861 | 54,952 | -246 |
EBITDA | -131,670 | -59,107 | -13,166 | -26,564 |
EBIT | -132,547 | -59,896 | -13,772 | -26,810 |
Net Income | -135,893 | -62,091 | -13,827 | -26,811 |
Net Change In Cash | 17,447 | 25,816 | 57,027 | 33,432 |
Cost of Revenue | -99,672 | 3,183 | 110,177 | |
Free Cash Flow | -122,995 | -49,536 | 3,162 | -21,594 |
Cash | 224,947 | 71,660 | 171,332 | 168,129 |
Basic Shares | 29,383 | 24,619 | 20,554 | 20,323 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.61 |
2024-06-30 | -$0.88 |
2024-03-31 | -$1.01 |
2023-12-31 | -$1.31 |
